Rothschedl, E. and Malikova, E. and Grössmann, N (2024): Daratumumab (Darzalex®) with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). Fact Sheet Nr. 191.

Rothschedl, E. and Malikova, E. and Grössmann, N. (2024): Mirvetuximab soravtansine (Elahere®) for the treatment of adults with folate receptor-alpha (FRα) positive epithelial ovarian, fallopian tube and primary peritoneal cancer. Fact Sheet Nr. 193.

Rothschedl, E and Malikova, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma. Fact Sheet Nr. 195.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Geiger-Gritsch, S. and Grössmann-Waniek, N. and Malikova, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease. Decision Support Document for the Austrian Appraisal Board 003.